Format

Send to

Choose Destination
See comment in PubMed Commons below
Biotechnol Prog. 2011 Nov-Dec;27(6):1744-50. doi: 10.1002/btpr.695. Epub 2011 Oct 14.

Optimization of a glycoengineered Pichia pastoris cultivation process for commercial antibody production.

Author information

1
Merck & Co., Inc., Bioprocess Research & Development, Rahway, NJ 07065, USA. Jianxin_Ye@merck.com

Abstract

Glycoengineering enabled the production of proteins with human N-linked glycans by Pichia pastoris. This study used a glycoengineered P. pastoris strain which is capable of producing humanized glycoprotein with terminal galactose for monoclonal antibody production. A design of experiments approach was used to optimize the process parameters. Followed by further optimization of the specific methanol feed rate, induction duration, and the initial induction biomass, the resulting process yielded up to 1.6 g/L of monoclonal antibody. This process was also scaled-up to 1,200-L scale, and the process profiles, productivity, and product quality were comparable with 30-L scale. The successful scale-up demonstrated that this glycoengineered P. pastoris fermentation process is a robust and commercially viable process.

PMID:
22002933
DOI:
10.1002/btpr.695
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center